Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0196
+0.0012 (6.52%)
Nov 2, 2026, 5:18 PM CET
Fidia Employees
Fidia had 143 employees as of June 30, 2026. That makes Fidia the 29,189th largest employer in the world and 244th in Italy.
Employees
143
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€164,238
Profits / Employee
€27,000
Market Cap
24.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 143 | - | - |
| Dec 31, 2025 | 146 | -13 | -8.18% |
| Dec 31, 2024 | 159 | -34 | -17.62% |
| Dec 31, 2023 | 193 | -4 | -2.03% |
| Dec 31, 2022 | 197 | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Danieli & C. Officine Meccaniche | 10,088 |
| Biesse | 3,601 |
| SIT S.p.A. | 1,916 |
| Tesmec | 937 |
| ILPRA | 429 |
| OSAI Automation System | 222 |
| Marzocchi Pompe | 220 |
| Valtecne | 181 |
Fidia News
- 1 hour ago - Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA - Investor's Business Daily
- 1 hour ago - Roche Granted FDA Clearance For Cobas Eplex Respiratory Pathogen Panel 3 - Nasdaq
- 3 hours ago - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters
- 4 hours ago - UniQure's Ifezuntirgene Inilparvovec BLA Gets FDA Priority Review Acceptance - Nasdaq
- 7 hours ago - Percheron's HMBD-002 Gets FDA Clearance For Blood Cancer Combination Trial - Nasdaq
- 8 hours ago - 1 Reason Compass Pathways Is Worth a Second Look This Month - The Motley Fool
- 9 hours ago - FDA Grants Neuren's NNZ-2591 Orphan Drug Designation For Newborn Encephalopathy - Nasdaq
- 1 day ago - Ajay Devgn's legal challenge won't halt proceedings, says Maharashtra FDA chief Tukaram Mundhe on Vimal Elaichi ad controversy - The Times of India